Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.292
Abstract: Background:Tyrosine kinase inhibitors (TKIs) have demonstrated clinical benefits in the treatment of several tumour types. However, the emergence of TKI resistance restricts the therapeutic effect. This study uses non-small cell lung cancer (NSCLC) to explore… read more here.
Keywords: tki resistance; resistance; akt foxm1; cancer ... See more keywords